Geode Capital Management LLC Increases Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Geode Capital Management LLC increased its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 912,599 shares of the medical instruments supplier’s stock after buying an additional 19,972 shares during the quarter. Geode Capital Management LLC’s holdings in Harvard Bioscience were worth $2,455,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in Harvard Bioscience by 13.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 274,635 shares of the medical instruments supplier’s stock valued at $783,000 after acquiring an additional 31,505 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in shares of Harvard Bioscience during the second quarter valued at $31,000. Rhumbline Advisers grew its holdings in shares of Harvard Bioscience by 24.9% in the second quarter. Rhumbline Advisers now owns 47,753 shares of the medical instruments supplier’s stock worth $136,000 after purchasing an additional 9,512 shares during the last quarter. Renaissance Technologies LLC increased its stake in Harvard Bioscience by 6.1% in the 2nd quarter. Renaissance Technologies LLC now owns 745,278 shares of the medical instruments supplier’s stock worth $2,124,000 after buying an additional 42,800 shares during the period. Finally, Gabelli Funds LLC bought a new stake in Harvard Bioscience during the 2nd quarter valued at about $128,000. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Price Performance

Shares of HBIO stock opened at $2.15 on Wednesday. The company has a market capitalization of $93.78 million, a P/E ratio of -6.51 and a beta of 1.27. The company’s 50-day simple moving average is $2.23 and its two-hundred day simple moving average is $2.61. Harvard Bioscience, Inc. has a one year low of $1.95 and a one year high of $4.99. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.